**Question:** ALLOSTERIC INHIBITION OF PFK-1 IS BY ALL EXCEPT ?

*Core Concept:* Allosteric inhibition is a type of regulation in which an effector molecule binds to a site other than the active site on a macromolecule, causing a conformational change that reduces the enzyme's activity. PFK-1 (Phosphofructokinase-1) is an enzyme that plays a crucial role in glycolysis, catalyzing the conversion of fructose-6-phosphate to fructose-1,6-bisphosphate.

**Why the Correct Answer is Right:** In the context of allosteric inhibition, PFK-1 is inhibited by its effector molecules, such as AMP (adenosine monophosphate), which binds to a regulatory site on the enzyme and decreases activity. Inhibition by AMP is an example of competitive inhibition, as it competes with ATP (adenosine triphosphate) for the regulatory site. However, AMP is not the only allosteric inhibitor of PFK-1.

**Why Each Wrong Option is Incorrect:**

A. **AMP**: AMP is a competitive inhibitor of PFK-1, binding to the regulatory site and decreasing the enzyme's affinity for its substrate (fructose-6-phosphate). This option is incorrect because it is a correct example of allosteric inhibition by PFK-1.

B. **Insulin**: Insulin is a hormone that promotes glucose uptake into cells, and its role in regulating PFK-1 activity is through allosteric activation, not inhibition.

C. **ATP**: ATP is an allosteric activator of PFK-1, binding to the regulatory site and increasing the enzyme's activity. This option is incorrect because it is a correct example of allosteric activation of PFK-1.

D. **FMN (FADH2)**: FMN (FADH2) is a cofactor (riboflavin) required for PFK-1 activity, not an inhibitor. This option is incorrect because it is a correct example of an essential cofactor rather than an allosteric inhibitor.

**Clinical Pearl:** Understanding allosteric regulation of enzymes like PFK-1 is crucial for understanding glucose homeostasis and cellular energy production. Inhibiting PFK-1 would lead to decreased glycolysis and ATP production, which could result in hypoglycemia, impaired cellular energy production, and other complications in patients with impaired glucose homeostasis.